Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.03) by 66.67 percent. This is a 85.71 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $1.051 million which missed the analyst consensus estimate of $1.233 million by 14.78 percent. This is a 33.23 percent decrease over sales of $1.574 million the same period last year.